Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Boineau

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
American Heart Journal|June 2, 2007
Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Brian Olshansky, Freda Wood, Anne S Hellkamp, et al.
Annals of Internal Medicine|February 4, 2014
Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trialGervasio A Lamas, Robin Boineau, Christine Goertz, et al.
Journal of the American Heart Association|November 7, 2012
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working groupKiran Musunuru, Dan M Roden, Robin Boineau, et al.
American Heart Journal|June 23, 2014
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation TherapyGervasio A Lamas, Robin Boineau, Christine Goertz, et al.
Circulation. Heart Failure|February 5, 2015
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist TrialCarine E Hamo, John F Heitner, Marc A Pfeffer, et al.
Circulation. Cardiovascular Quality and Outcomes|November 21, 2013
The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT)Esteban Escolar, Gervasio A Lamas, Daniel B Mark, et al.
Circulation. Cardiovascular Quality and Outcomes|July 3, 2014
Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trialDaniel B Mark, Kevin J Anstrom, Nancy E Clapp-Channing, et al.
American Heart Journal|December 6, 2011
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAkshay S Desai, Eldrin F Lewis, Rebecca Li, et al.
The New England Journal of Medicine|January 22, 2005
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failureGust H Bardy, Kerry L Lee, Daniel B Mark, et al.
Circulation|December 4, 2013
Pulseless electric activity: definition, causes, mechanisms, management, and research priorities for the next decade: report from a National Heart, Lung, and Blood Institute workshopRobert J Myerburg, Henry Halperin, Debra A Egan, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
American Heart Journal|June 2, 2007
Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Brian Olshansky, Freda Wood, Anne S Hellkamp, et al.
Annals of Internal Medicine|February 4, 2014
Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trialGervasio A Lamas, Robin Boineau, Christine Goertz, et al.
Journal of the American Heart Association|November 7, 2012
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working groupKiran Musunuru, Dan M Roden, Robin Boineau, et al.
American Heart Journal|June 23, 2014
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation TherapyGervasio A Lamas, Robin Boineau, Christine Goertz, et al.
Circulation. Heart Failure|February 5, 2015
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist TrialCarine E Hamo, John F Heitner, Marc A Pfeffer, et al.
Circulation. Cardiovascular Quality and Outcomes|November 21, 2013
The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT)Esteban Escolar, Gervasio A Lamas, Daniel B Mark, et al.
Circulation. Cardiovascular Quality and Outcomes|July 3, 2014
Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trialDaniel B Mark, Kevin J Anstrom, Nancy E Clapp-Channing, et al.
American Heart Journal|December 6, 2011
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAkshay S Desai, Eldrin F Lewis, Rebecca Li, et al.
The New England Journal of Medicine|January 22, 2005
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failureGust H Bardy, Kerry L Lee, Daniel B Mark, et al.
Circulation|December 4, 2013
Pulseless electric activity: definition, causes, mechanisms, management, and research priorities for the next decade: report from a National Heart, Lung, and Blood Institute workshopRobert J Myerburg, Henry Halperin, Debra A Egan, et al.
Pageof 4